{"title":"Combined anti-PD1 immunotherapy for patient with advanced pancreatic cancer: A case report","authors":"Zhe Jiang, Hongyan Li, Fei Li","doi":"10.36922/td.v1i1.52","DOIUrl":null,"url":null,"abstract":"Pancreatic cancer (PC) is a highly lethal malignancy with a dismal 5-year survival rate. The current treatment modalities for the treatment-associated toxicity of immunotherapy-based approaches are limited. Immunotherapy for PC was needed to be further investigated. This report illustrates the combined use of anti PD-1 immunotherapy with other therapeutic strategies for cancer pain. In this case, a patient with PC was treated with surgical resection, chemotherapy, molecular targeted medicine, and anti-PD1 immunotherapy. The survival period of the patient was more than 6 years since diagnosis. Finally, we will present our perspective on the future development of immunotherapy for PC. In a word, this case report sheds lights on information that would be helpful for more rigorous exploration of PC treatments.","PeriodicalId":94260,"journal":{"name":"Tumor discovery","volume":"70 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumor discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36922/td.v1i1.52","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Pancreatic cancer (PC) is a highly lethal malignancy with a dismal 5-year survival rate. The current treatment modalities for the treatment-associated toxicity of immunotherapy-based approaches are limited. Immunotherapy for PC was needed to be further investigated. This report illustrates the combined use of anti PD-1 immunotherapy with other therapeutic strategies for cancer pain. In this case, a patient with PC was treated with surgical resection, chemotherapy, molecular targeted medicine, and anti-PD1 immunotherapy. The survival period of the patient was more than 6 years since diagnosis. Finally, we will present our perspective on the future development of immunotherapy for PC. In a word, this case report sheds lights on information that would be helpful for more rigorous exploration of PC treatments.